Removing a hair of doubt about BRAF targeting

Blood. 2015 Feb 19;125(8):1199-200. doi: 10.1182/blood-2014-12-616318.

Abstract

In this issue of Blood, Pettirossi et al, including Drs Tiacci and Falini, who led the effort in 2011 defining the BRAF-V600E driving mutation in hairy cell leukemia (HCL),provide extensive laboratory studies showing that inhibitors of BRAF-V600E and/or mitogen-activated protein kinase kinase (MEK) reach their targets and cause HCL cell death

Publication types

  • Comment

MeSH terms

  • Antineoplastic Agents*
  • Humans
  • Imidazoles*
  • Indoles*
  • Leukemia, Hairy Cell / drug therapy*
  • Leukemia, Hairy Cell / genetics*
  • Oximes*
  • Pyridones*
  • Pyrimidinones*
  • Sulfonamides*
  • Transcriptome / drug effects*
  • Vemurafenib

Substances

  • Antineoplastic Agents
  • Imidazoles
  • Indoles
  • Oximes
  • Pyridones
  • Pyrimidinones
  • Sulfonamides
  • Vemurafenib
  • trametinib
  • dabrafenib